Michael J. Fox Foundation and 23andMe Launch Fox DEN
The Michael J. Fox Foundation for Parkinson's Research and 23andMe have launched the Fox Insight Data Exploration Network. Fox DEN contains patient-reported outcomes, de-identified genetic data and data exploration tools from the largest cohort in Parkinson's disease research. The network features information from surveys on health and disease, symptoms, daily activities, and other factors relevant to Parkinson's coupled with genetic information from 23andMe customers who have joined the Fox Insight study.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Tirzepatide Demonstrates Superior Weight Loss to Semaglutide in 72-Week Phase IIIb SURMOUNT-5 Trial
May 12th 2025In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist tirzepatide (Zepbound) delivered significantly greater and sustained weight loss than semaglutide (Wegovy) over 72 weeks in adults with obesity or overweight and comorbidities.
